博舒替尼对比伊马替尼一线治疗新诊断慢性髓性白血病:随机BFORE试验结果
这项正在进行的国际多中心III期随机试验将536例新诊断慢性期CML患者按1:1分配至博舒替尼400 mg每日一次组(n=268)或伊马替尼组(n=268)。在意向治疗人群中,博舒替尼组12个月主要分子学缓解率显著高于伊马替尼组(47.2% vs 36.9%,P=0.02),完全细胞遗传学缓解率亦更高(77.2% vs 66.4%,P=0.0075),且缓解出现更早;胃肠道事件和转氨酶升高在博舒替尼组更常见。
要点
- 博舒替尼组12个月MMR率47.2%,伊马替尼组36.9%(P=0.02),差异显著。
- 博舒替尼组12个月内CCyR率77.2%,伊马替尼组66.4%(P=0.0075)。
- 博舒替尼组≥3级腹泻7.8% vs 0.8%,ALT升高19.0% vs 1.5%,AST升高9.7% vs 1.9%。
核心结论
- 博舒替尼组MMR和CCyR率显著高于伊马替尼组,且缓解出现更早。
- 胃肠道事件和转氨酶升高在博舒替尼组更常见,与已知安全性特征一致。
- 结果提示博舒替尼可能成为慢性期CML的有效一线治疗。
研究设计与样本
- 正在进行的国际多中心III期随机试验,536例新诊断慢性期CML患者按1:1随机分配。
- 博舒替尼400 mg每日一次组268例,伊马替尼组268例。
- 疗效按方案在费城染色体阳性且具有典型e13a2/e14a2转录本的患者中评估(博舒替尼246例,伊马替尼241例)。
主要发现
- 12个月MMR率(主要终点)博舒替尼组47.2% vs 伊马替尼组36.9%(P=0.02)。
- 12个月内CCyR率博舒替尼组77.2% vs 伊马替尼组66.4%(P=0.0075)。
- 累积发生率有利于博舒替尼:MMR风险比1.34(P=0.0173),CCyR风险比1.38(P<0.001),且缓解时间更早。
- 疾病进展至加速/急变期:博舒替尼组4例(1.6%),伊马替尼组6例(2.5%)。
- 治疗患者中停药:博舒替尼组22.0%,伊马替尼组26.8%;最常见原因为药物相关毒性(分别为12.7%和8.7%)。
关键数值与推荐
- ≥3级腹泻:博舒替尼组7.8% vs 伊马替尼组0.8%。
- ALT升高:博舒替尼组19.0% vs 伊马替尼组1.5%;AST升高:博舒替尼组9.7% vs 伊马替尼组1.9%。
- 心脏和血管毒性不常见。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Bosutinib is a potent dual SRC/ABL kinase inhibitor approved for adults with Philadelphia chromosome-positive chronic myeloid leukemia (CML) resistant and /or intolerant to prior therapy. We assessed the efficacy and safety of bosutinib versus imatinib for first-line treatment of chronic-phase CML. Methods In this ongoing, multinational, phase III study, 536 patients with newly diagnosed chronic-phase CML were randomly assigned 1:1 to receive 400 mg of bosutinib once daily (n = 268) or imatinib (n = 268). Per protocol, efficacy was assessed in patients who were Philadelphia chromosome-positive with typical (e13a2/e14a2) transcripts (bosutinib, n = 246; imatinib, n = 241). Patients with Philadelphia chromosome-negative-/ BCR-ABL1-positive status and those with unknown Philadelphia chromosome status and/or atypical BCR-ABL1 transcript type were excluded from this population. Results The major molecular response (MMR) rate at 12 months (primary end point) was significantly higher with bosutinib versus imatinib (47.2% v 36.9%, respectively; P = .02), as was complete cytogenetic response (CCyR) rate by 12 months (77.2% v 66.4%, respectively; P = .0075). Cumulative incidence was favorable with bosutinib (MMR: hazard ratio, 1.34; P = .0173; CCyR: hazard ratio, 1.38; P < .001), with earlier response times. Four patients (1.6%) receiving bosutinib and six patients (2.5%) receiving imatinib experienced disease progression to accelerated/blast phase. Among treated patients, 22.0% of patients receiving bosutinib and 26.8% of patients receiving imatinib discontinued treatment, most commonly for drug-related toxicity (12.7% and 8.7%, respectively). Grade ≥ 3 diarrhea (7.8% v 0.8%) and increased ALT (19.0% v 1.5%) and AST (9.7% v 1.9%) levels were more common with bosutinib. Cardiac and vascular toxicities were uncommon. Conclusion Patients who received bosutinib had significantly higher rates of MMR and CCyR and achieved responses faster than those who received imatinib. Consistent with the known safety profile, GI events and transaminase elevations were more common with bosutinib. Results indicate bosutinib may be an effective first-line treatment for chronic-phase CML.
引用
- Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol. 2017. PMID: 29091516. doi:10.1200/JCO.2017.74.7162
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。